Source comparison
Selank Amidate vs Thymosin Alpha-1: Direct Comparison
The following table summarizes the core differences between Selank Amidate and Thymosin Alpha-1 across structural, mechanistic, and application domains. Amino Acid Length 7 amino acids (heptapeptide) 28 amino acids (polypeptide) Structural complexity differs s
This comparison does not assign a generated winner or score.
- The following table summarizes the core differences between Selank Amidate and Thymosin Alpha-1 across structural, mechanistic, and application domains.
- Amino Acid Length
- 7 amino acids (heptapeptide)
- 28 amino acids (polypeptide)
- Structural complexity differs significantly—Thymosin Alpha-1's longer sequence provides more epitope diversity for immune receptor engagement
- Primary Mechanism
- GABA receptor modulation, enkephalin stabilization, BDNF upregulation
- TLR2/TLR9 activation, cytokine upregulation (IL-2, IFN-γ), T-cell maturation
- Entirely distinct receptor pathways—no mechanistic overlap between neurological and immune signaling
- Half-Life (Subcutaneous)
- 20–30 minutes (amidated form)
- ~2 hours
- Thymosin Alpha-1's extended half-life allows less frequent dosing in research protocols
- Target Organ System
- Central nervous system (prefrontal cortex, hippocampus)
- Lymphoid tissue (thymus, spleen, lymph nodes)
- System-level distinction determines research application—neurological vs immunological endpoints
- Research Dosage Range
- 300–600 mcg/kg (intranasal or subcutaneous)
- 1.6 mg twice weekly (subcutaneous)
- Dosing schedules reflect pharmacokinetic differences—Selank requires more frequent administration
- Primary Research Applications
- Anxiety modulation, cognitive enhancement, stress resilience
- Immune reconstitution, viral infection adjunct, cancer immunotherapy
- Application domains don't compete—selection depends entirely on study objective
- Notable Clinical Findings
- 14-day intranasal administration reduced Hamilton Anxiety scores comparably to SSRIs in human trials
- 6-month subcutaneous regimen increased HBeAg seroconversion by 26 percentage points in hepatitis B trials
- Both show statistically significant effects in their respective domains—evidence quality is comparable